These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 21747083

  • 1. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.
    J Clin Oncol; 2011 Aug 10; 29(23):3179-84. PubMed ID: 21747083
    [Abstract] [Full Text] [Related]

  • 2. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
    Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.
    Leukemia; 2012 Apr 10; 26(4):716-9. PubMed ID: 21926959
    [Abstract] [Full Text] [Related]

  • 3. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan 10; 33(1):25-30. PubMed ID: 22575188
    [Abstract] [Full Text] [Related]

  • 4. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A, Shide K, Kameda T, Ito M, Sekine M, Kubuki Y, Hidaka T, Akizuki K, Tahira Y, Toyama T, Kawano N, Marutsuka K, Maeda K, Takeuchi M, Kawano H, Sato S, Ishizaki J, Shimoda H, Yamashita K, Matsuoka H, Shimoda K.
    Int J Hematol; 2018 Oct 10; 108(4):411-415. PubMed ID: 29987745
    [Abstract] [Full Text] [Related]

  • 5. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
    Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC.
    Histopathology; 2010 May 10; 56(6):758-67. PubMed ID: 20546341
    [Abstract] [Full Text] [Related]

  • 6. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 10; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 7. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J, Kvasnicka HM, Zankovich R, Diehl V.
    Haematologica; 2000 Nov 10; 85(11):1126-34. PubMed ID: 11064463
    [Abstract] [Full Text] [Related]

  • 8. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A.
    Leukemia; 2013 Oct 10; 27(10):1953-8. PubMed ID: 23467025
    [Abstract] [Full Text] [Related]

  • 9. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
    Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B.
    Eur J Haematol; 2011 Feb 10; 86(2):148-55. PubMed ID: 21059102
    [Abstract] [Full Text] [Related]

  • 10. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.
    Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini AR, Federici I, Giantomassi F, Da Lio L, Zizzi A, Honorati E, Leoni P.
    Diagn Pathol; 2015 Apr 16; 10():29. PubMed ID: 25885405
    [Abstract] [Full Text] [Related]

  • 11. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.
    Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A.
    Blood; 2012 Jul 19; 120(3):569-71. PubMed ID: 22700720
    [Abstract] [Full Text] [Related]

  • 12. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb 19; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 13. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
    Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N.
    Eur J Haematol; 2019 Jun 19; 102(6):516-520. PubMed ID: 30977935
    [Abstract] [Full Text] [Related]

  • 14. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
    Thiele J, Kvasnicka HM.
    Ann Hematol; 2003 Mar 19; 82(3):148-52. PubMed ID: 12634946
    [Abstract] [Full Text] [Related]

  • 15. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A.
    Blood Cancer J; 2015 Aug 14; 5(8):e337. PubMed ID: 26832847
    [Abstract] [Full Text] [Related]

  • 16. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V.
    Am J Hematol; 2002 Aug 14; 70(4):283-91. PubMed ID: 12210809
    [Abstract] [Full Text] [Related]

  • 17. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.
    Mudireddy M, Barraco D, Hanson CA, Pardanani A, Gangat N, Tefferi A.
    Am J Hematol; 2017 May 14; 92(5):454-459. PubMed ID: 28211153
    [Abstract] [Full Text] [Related]

  • 18. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC.
    APMIS; 2011 Aug 14; 119(8):498-504. PubMed ID: 21749449
    [Abstract] [Full Text] [Related]

  • 19. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2014 Sep 14; 89(9):915-25. PubMed ID: 25124313
    [Abstract] [Full Text] [Related]

  • 20. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J.
    Leuk Res; 2007 Aug 14; 31(8):1031-8. PubMed ID: 17367853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.